Indraprastha Medical Corporation LimitedQ2 FY27 Results & Financial Update
Indraprastha Medical Corporation Limited: Q2 FY27 standalone results and company financials – revenue ₹412.85 Cr, PAT ₹53.58 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Indraprastha Medical Corporation price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Indraprastha Medical Corporation Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Indraprastha Medical Corporation Limited reported standalone revenue from operations of INR 412.85 crore for the quarter ended September 30, 2026, representing a sequential increase of 1.65% compared to INR 406.15 crore in the preceding quarter ended June 30, 2026.
Total income for Q2 FY27 stood at INR 421.40 crore, up 1.65% sequentially from INR 414.57 crore, bolstered by steady other income of INR 8.55 crore.
Profit before tax (PBT) for the quarter was recorded at INR 72.07 crore, reflecting a sequential decrease of 3.68% compared to INR 74.82 crore in Q1 FY27, as total expenses expanded to INR 349.33 crore.
Profit after tax (PAT) for the period came in at INR 53.58 crore, down 4.06% sequentially from INR 55.85 crore in the previous quarter, resulting in basic and diluted earnings per share (EPS) of INR 5.84 compared to INR 6.09 in Q1 FY27.
The PAT margin contracted by 77 basis points sequentially from 13.75% in the first quarter of FY27 to 12.98% in the current quarter under review.
Total expenses for the quarter rose to INR 349.33 crore from INR 339.75 crore in Q1 FY27, driven by higher consumption of materials and increased employee benefit expenses.
01 · Business model
What does Indraprastha Medical Corporation do?
Indraprastha Medical Corporation Limited operates healthcare facilities under the Indraprastha Apollo Hospitals brand, providing comprehensive medical and surgical services primarily at its flagship tertiary-care hospital located in New Delhi.
The company generates its primary revenue streams from inpatient and outpatient medical services, diagnostic investigations, pharmaceutical sales, and specialized clinical treatments delivered by resident and visiting medical professionals.
The economic and operating model relies heavily on high-end medical infrastructure, specialized physician engagements, and efficient bed-occupancy management to sustain profitability amidst competitive metropolitan healthcare markets.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹412.85 Cr | ₹406.15 Cr |
| Total income | ₹421.40 Cr | ₹414.57 Cr |
| Profit before tax | ₹72.07 Cr | ₹74.82 Cr |
| Profit after tax | ₹53.58 Cr | ₹55.85 Cr |
| EPS | ₹5.84 | ₹6.09 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 13.0% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 17.5% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹8.55 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations rose to INR 412.85 crore in Q2 FY27, marking a 1.65% increase over the INR 406.15 crore reported in Q1 FY27.
Total income reached INR 421.40 crore, supported by INR 8.55 crore in other income, reflecting consistent operational momentum.
What drove margins
Material costs decreased sequentially to INR 67.42 crore in Q2 FY27 from INR 70.13 crore in Q1 FY27.
Employee costs increased to INR 78.53 crore during the quarter compared to INR 72.96 crore in the preceding period.
Professional fees paid to doctors remained stable at INR 111.53 crore, virtually unchanged from INR 111.15 crore in Q1 FY27.
Other expenses stood at INR 77.93 crore compared to INR 72.10 crore in the previous quarter.
04 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates in a single primary business segment, namely Healthcare, in accordance with Ind AS 108.
05 · Reported developments
What changed operationally
Revenue from operations improved sequentially to INR 412.85 crore in Q2 FY27.
06 · Pressure points & risks
What is not going smoothly
PAT margin declined by approximately 77 basis points sequentially to 12.98% due to rising employee and operating expenses.
07 · Items worth noticing
The line items that can distort a quick read
The company recorded provisions of INR 3.20 crore during the quarter ended September 30, 2026.
08 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
For the half-year ended September 30, 2026, net cash generated from operating activities stood at INR 109.35 crore.
Net cash used in investing activities for the half-year ended September 30, 2026, was INR 101.38 crore, reflecting investments in property, plant, equipment, and mutual funds.
Net cash used in financing activities for the half-year ended September 30, 2026, was INR 6.42 crore, which included lease and interest payments.
09 · Beyond the numbers
What changed beyond the numbers
Reported update
Board Approval
The unaudited financial results for the quarter and half-year ended September 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 29, 2026.
10 · Previous-quarter changes
What changed since the previous quarter
Total expenses rose from INR 339.75 crore in Q1 FY27 to INR 349.33 crore in Q2 FY27, primarily led by higher employee and other operational costs.
11 · Key Q&A
The quarter, answered directly
What does Indraprastha Medical Corporation do?
Indraprastha Medical Corporation Limited operates healthcare facilities under the Indraprastha Apollo Hospitals brand, providing comprehensive medical and surgical services primarily at its flagship tertiary-care hospital located in New Delhi.
What is the clearest takeaway from Q2 FY27?
Indraprastha Medical Corporation Limited reported standalone revenue from operations of INR 412.85 crore for the quarter ended September 30, 2026, representing a sequential increase of 1.65% compared to INR 406.15 crore in the preceding quarter ended June 30, 2026.
What drove revenue or demand?
Revenue from operations rose to INR 412.85 crore in Q2 FY27, marking a 1.65% increase over the INR 406.15 crore reported in Q1 FY27.
What mattered most for margins or profitability?
Material costs decreased sequentially to INR 67.42 crore in Q2 FY27 from INR 70.13 crore in Q1 FY27.
What changed operationally beyond the headline numbers?
The unaudited financial results for the quarter and half-year ended September 30, 2026, were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 29, 2026.
What are the main pressure points disclosed for the quarter?
PAT margin declined by approximately 77 basis points sequentially to 12.98% due to rising employee and operating expenses.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
13 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Financial Reporting: Monitor upcoming quarterly disclosures for trends in healthcare service realization and cost containment.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.